Guanhui Wu

Dr. Guanhui Wu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2012 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Closed access
PDF file
XCXiqun Chen
Xiqun Chen
GWGuanhui Wu
Guanhui Wu
MSMichael A. Schwarzschild
Michael A. Schwarzschild

1 September 2024 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
QGQian Gui
Qian Gui
JMJingcai Meng
Jingcai Meng
MSMingqiang Shen
Mingqiang Shen
HFHongxuan Feng
Hongxuan Feng
XDXiaofeng Dong
Xiaofeng Dong
YLYanli Lu
Yanli Lu
Introduction: Previous studies have predominantly explored the relationship of the glymphatic system with motor symptoms in Parkinson’s disease (PD); however, research on non-motor symptoms remains limited. Therefore, this study investigated the association between glymphatic function and non-motor symptoms, including cognitive impairment and sleep disorders, in PD patients. Methods: This study recruited 49 PD patients and 38 healthy controls (HC). Glymphatic function was evaluated using enlarged perivascular spaces (EPVS) in the basal ganglia (BG) region and diffusion tensor image analysis along the perivascular space (DTI-ALPS) index. Cognition, sleep, anxiety, and depression scales were assessed in all participants. According to the scale scores, PD patients were further divided into several groups to identify the presence of non-motor symptoms. Differences in EPVS numbers and ALPS index between PD subgroups and HC group were compared. Spearman correlation analysis was performed to investigate the association between the PD non-motor symptoms and ALPS index. Additionally, receiver operating characteristic (ROC) curves analysis was conducted for ALPS index to predict cognitive impairment and insomnia in PD patients. Results: PD patients with and without non-motor symptoms all showed more EPVS numbers than the controls, and the EPVS numbers in PD patients with cognitive impairment were also greater than those without. Notably, except for the depression subgroup, PD patients with non-motor symptoms showed significantly lower ALPS index than the controls. The Montreal Cognitive Assessment (MoCA) scores were positively correlated, whereas the Parkinson’s Disease Sleep Scale (PDSS)-2 and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) scores were negatively correlated with the ALPS index in PD patients (r=0.3618, P=0.0053; r=− 0.4146, P=0.0015; r=− 0.2655, P=0.0326, respectively). The ALPS index proved to be predictive of cognitive impairment and insomnia in PD patients (AUC=0.7733, P=0.001; AUC=0.7993, P=0.0004, respectively). Conclusion: Glymphatic function is closely associated with cognition and sleep of PD patients.

6 March 2017 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
GWGuanhui Wu
Guanhui Wu
FKFan-Zhen Kong
Fan-Zhen Kong
XDXiao-Feng Dong
Xiao-Feng Dong
DWDe-Feng Wu
De-Feng Wu
QGQian-Zhu Guo
Qian-Zhu Guo
WLWei-Feng Luo
Wei-Feng Luo

27 November 2024 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
JYJia Yan
Jia Yan
SYShuai Yu
Shuai Yu
HFHongxuan Feng
Hongxuan Feng
HZHuimin Zhao
Huimin Zhao
XDXiaofeng Dong
Xiaofeng Dong
GWGuanhui Wu
Guanhui Wu
Patients with stroke due to large artery atherosclerosis are at risk of early progression and recurrence. The efficacy and safety of argatroban in stroke patients who did not receive reperfusion therapy, and which patients may benefit from it, are uncertain. We conducted a cohort study to assess whether argatroban given within 72 hours of symptom onset, combined with antiplatelet therapy, improved neurological outcomes of patients with acute mild to moderate ischemic stroke in China. Patients were divided into the combined treatment group and the control group. Inverse probability of treatment weighting was used to balance baseline covariates. The primary efficacy outcome is the proportion of mRS score 0-2 at 90 days. The secondary efficacy outcomes included END proportion, change in NIHSS score from the baseline to day 7, recurrent cardiovascular events, and cardiovascular death. The safety outcomes were hemorrhagic transformation (HT) of infarction and organ hemorrhage at 7 days. Compared with the control group, a higher proportion of mRS (0-2) at 90 days was found in patients in the combined treatment group (85.3% vs 74.5%, p=0.042). There was no significant difference in the safety outcomes between the two groups. Exploratory subgroup analysis showed positive associations with argatroban combined therapy and good prognosis in NIHSS score ≥5 and age ≥70 subgroups. Our study suggested that argatroban can improve neurological outcomes for mild to moderate LAA patients but not increase the risk of bleeding.

1 January 2014
Verified
Journal Article
Closed access
GWGuanhui Wu
Guanhui Wu
FKFan-Zhen Kong
Fan-Zhen Kong
QCQing-Zhang Cheng
Qing-Zhang Cheng
WLWei-Feng Luo
Wei-Feng Luo
XDXiang-Dong Du
Xiang-Dong Du

11 November 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SYShuai Yu
Shuai Yu
JYJia Yan
Jia Yan
RLRobert Logan
Robert Logan
WTWei-Ting Tang
Wei-Ting Tang
JYJun-Nan Ye
Jun-Nan Ye
TDTing-Ting Duan
Ting-Ting Duan
Objective: Ischemic stroke-associated pneumonia (iSAP) affects about 10% of acute ischemic stroke patients during hospitalization. Current prediction scales for iSAP are insufficient. Identifying early biomarkers for stroke-associated pneumonia is crucial for improving patient outcomes. This study aimed to investigate the predictive value of euthyroid sick syndrome (ESS) for iSAP in acute-stage of ischemic stroke patients.Methods: We studied 1767 acute ischemic stroke patients within one week of symptom onset, categorizing them into an infection group (iSAP, n=376) and control group (control, n=1391). COX regression analysis was used to identify the potential risk and protected factors. Kaplan-Meier time-event curves and Log-Rank tests were performed to differentiate infection time in patients with ESS or normal T3 group.Results: The iSAP group had higher rates of risk factors like older age, atrial fibrillation, COPD, and ESS, along with elevated levels of WBC, CRP,and FT4 levels (all P < 0.001). Conversely, iSAP patients had lower GCS scores, eGFR, TSH, T3, FT3 (all P < 0.001) and T4 levels (P = 0.005) upon admission. No significant differences were observed in sex, smoking history, hypertension, diabetes, or LDL-C levels (P > 0.05). COX regression analysis identified age, KWST scores, leukocyte count, CRP, and ESS (all P < 0.001) as significantly correlated with iSAP. ROC analysis revealed ESS as a predictor with sensitivity of 35.64% and specificity of 87.92% for SAP prediction, like atrial fibrillation and higher than COPD and eGFR.Conclusion: ESS at admission predicts a higher risk of stroke-associated pneumonia in acute-stage of ischemic stroke.